Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in thailand

Clinical Therapeutics

Volumn 32, Issue 10, 2010, Pages 1842-1853

  Boonleang, Jutima ^a   Pipatrattanaseree, Weerachai ^b   Tanthana, Chanpa ^a   Mahatthanatrakul, Werawath ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b Drug Section   (Thailand)

Author keywords

9 hydroxyrisperidone; Atypical antipsychotics; Bioavailability; Bioequivalence; Pharmacokinetics; Risperidone

Indexed keywords

IPERDAL; PALIPERIDONE; RISCON; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ION TRAP MASS SPECTROMETRY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; SYNCOPE; TABLET FORMULATION; THAILAND;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUGS, GENERIC; HUMANS; ISOXAZOLES; MALE; PYRIMIDINES; RISPERIDONE; TABLETS; THAILAND; YOUNG ADULT;

EID: 78650591209     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.09.013     Document Type: Article

References (35)

1. Risperidone. AHFS Drug Information 2009 2009, 2499-2505. American Society of Health System Pharmacists, Bethesda, Md. G.K. McEvoy (Ed.).
2. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations US Dept of Health and Human Services, US Food and Drug Administration, Accessed May 5, 2007. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020272&TABLE1=OB_Rx.
3. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed dose of risperidone and haloperidol in the treatment of chronic schizophrenic patients [published correction appears in J Clin Psychopharmacol. 1993;13:149]. J Clin Psychopharmacol 1993, 13:25-40.
4. Marder SR, Meibach RC Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994, 151:825-835.
5. Trevitt JT, Lyons M, Aberman J, et al. Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function. Psychopharmacology (Berl). 1997, 132:74-81.
6. Yen YC, Lung FW, Chong MY Adverse effects of risperidone and haloperidol treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004, 28:285-290.
7. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos. 1993, 21:1134-1141.
8. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res. 2007, 90:147-161.
9. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993, 54:257-268.
10. Grant S, Fitton A Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994, 48:253-273.
11. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988, 247:661-670.
12. van Beijsterveldt LE, Geerts RJ, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl). 1994, 114:53-62.
13. Megens AA, Awouters FH In vivo pharmacological profile of 9-hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone. Drug Dev Res. 1994, 33:399-412.
14. Aravagiri M, Yuwiler A, Marder SR Distribution after repeated oral ad- ministration of different dose levels of risperidone and 9-hydroxy- risperidone in the brain and other tissues of rat. Psychopharmacology (Berl). 1998, 139:356-363.
15. Mahatthanatrakul W, Nontaput T, Sriwiriyajan S, Ridtitid W Bioequivalence study of a generic risperidone (Iperdal) in healthy Thai male volunteers. Songklanakarin J Sci Technol. 2008, 30:307-312.
16. Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005, 19:395-401.
17. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Saf. 2006, 29:587-598.
18. ASEAN guidelines for the conduct of bioavailability and bioequivalence studies 2004, Association of Southeast Asian Na- tions (ASEAN), Consultative Com- mittee for Standards and Quality-Pharmaceutical Product Working groupConsultative Com- mittee for Standards and Quality-Pharmaceutical Product Working group, Accessed January 20, 2007. http://www.fda.moph.go.th.
19. Thailand Guidelines for the conduct of bioavailability and bioequivalence studies 2005, Drug Control Division, Food and Drug Administration, Ministry of Public Health, Accessed January 20, 2007. http://www.fda.moph.go.th.
20. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assem- bly, Edinburgh, Scotland October 2000, World Medical Association Decla-ration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects, Accessed June 20, 2006. http://www.wma.net/en/30publications/10policies/b3/index.html.
21. Guideline for Good Clinical Practice. ICH Topic E 6 European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health OrganizationInternational Conference on Harmonisation-World Health Organization, Accessed June 20, 2006. http://www.eortc.be/Services/Doc/ICH_GCP.pdf.
22. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations 2002, US Dept of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Accessed January 14, 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
23. Bioanalytical method validation 2001, US Dept of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Center for Veterinary MedicineCenter for Veterinary Medicine, Guidance for IndustryGuidance for Industry, Accessed January 14, 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
24. van Schaick EA, Lechat P, Remmerie BM, et al. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003, 25:1687-1699.
25. Bolton S Pharmaceutical Statistics: Practical and Clinical Applications 1997, 210-212. Marcel Dekker, New York, NY, 405-418. 3rd ed.
26. Yuh L Statistical consideration for bioavailability/bioequivalence studies. Pharmacokinetics: Regulatory, Industrial, Academic Perspectives 1995, 479-502. Marcel Dekker, New York, NY. 2nd ed. P.G. Welling, L.S. Tse Francis (Eds.).
27. Guidance for Industry. Statistical approaches to establishing bioequivalence 2001, US Dept of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Accessed January 15, 2006. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf.
28. Liu JP, Chow SC Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm. 1992, 20:101-104.
29. Chow SC, Wang H On sample size calculation in bioequivalence trials [published correction appears in J Pharmacokinet Pharmacodyn. 2002; 29:101]. J Pharmcokinet Pharmacodyn 2001, 28:155-169.
30. Nowatzke W, Woolf E Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standard, quality controls and study samples. AAPS J. 2007, 9:E117-E122.
31. Thyssen A, Remmerie B, D'Hoore P, et al. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: A summary of ten phase I clinical trials assessing taste, tablet disintegrating time, bioequivalence, and tolerability. Clin Ther. 2007, 29:290-304.
32. Kousoulos C, Dotsikas Y, Loukas YL Turbulent flow and ternary column-switching on-line clean-up system for high-throughput quantification of risperidone and its main metabolite by LC-MS/MS application to a bioequivalence study. Talanta. 2007, 72:360-367.
33. Cánovas M, Delgadillo J, Torres F, et al. Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2009, 47:124-131.
34. Blume HH, Midha KK Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1993, 82:1186-1189.
35. Borison RL, Diamond B, Pathiraja A, Meibach RC Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull. 1994, 30:193-197.